Minister for Jobs, Enterprise and Innovation, Richard Bruton, TD today announced that Synowledge, an Indian company specialising in the provision of drug safety and regulatory affairs services for the pharmaceutical, biotechnology and medical device sectors, is to establish an international headquarters in Dublin with the creation of 35 new high quality jobs.
The announcement was made as part of the Minister’s trade and investment mission to India and the investment is supported by the Department of Jobs, Enterprise and Innovation, through IDA Ireland.
Activities carried out at the new international headquarters will include business development for non-US markets, near shore servicing and IP management. The Irish operation will carry out sales and marketing for the entire Synowledge product portfolio and will provide near shore delivery of the company’s pharmacovigilance, regulatory and IT services to Europe.
Speaking following a meeting with the company at Synowledge headquarters in Bangalore, Minister Bruton TD said: “The life sciences industry is a key part of this government’s strategy for jobs and growth, and through our Action Plan for Jobs we have put in place a range of measures to support jobs growth in the sector. This announcement by Synowledge that it is to establish its international headquarters in Dublin with the creation of 35 new high quality jobs is further endorsement of our ongoing efforts to attract new and innovative companies to invest and grow their business in Ireland. Through continued implementation of our plan, I am determined to ensure that we can see more announcements like this”.
Welcoming the announcement Sankesh Abbhi, President and CEO of Synowledge said, ‘”Having grown exponentially since we began operations in 2009, we were proud to be recognized recently as one of the fastest growing private companies in the US. Our growth is based on our focus on excellence, our people and our clients. We are able to manage such dynamic change because of our agility and ability to locate strategically to best serve our clients. Ireland was a logical choice for our International base to seamlessly connect with our US HQ and our delivery centers in Europe, India and Japan. Being in the drug safety, IT and regulatory affairs fields, Ireland’s profile as a hub for the global life science sector and its cosmopolitan talent pool, were also key factors in our decision. We are confident that Ireland will add value to our clients and further fuel our growth trajectory.”
Commenting on the announcement, Barry O’Leary, CEO of IDA Ireland said, ‘Synowledge will become an important part of the pharmaceutical regulation and compliance industry in Ireland. In addition, Synowledge is predominately Indian-based and represent an important win for IDA Ireland as we develop our pipeline of Indian companies.’